Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/19/2011

to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California, and has a commercial manufacturing facility in Ohio. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or BYDUREON, and the revenues or royalties generated from these products, may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that the CMC section of the metreleptin BLA may not be submitted in a timely fashion or that the BLA will not receive regulatory approval; risks that our preclinical studies or the data analyses mentioned in this press release may not be predictive; risks that our NDAs for product candidates, such as the BYDUREON NDA, or sNDAs for label expansion requests, may not be submitted timely or receive FDA approval; risks that the information we provide in our response to the FDA's BYDUREON complete response letter may not satisfy the FDA; risks that the FDA may request additional information prior to approving BYDUREON; risks that the launch of BYDUREON, if approved, will be delayed; risks that our expense reductions will not be as large as we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and prici
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Third Quarter Results
2. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
7. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
8. Lilly Comments on Court Ruling in Amylin Litigation
9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
10. Lilly Provides Its Perspective in Response to Amylin Lawsuit
11. Lilly Provides Statement in Response to Amylin Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  Abbott (NYSE: ABT ) announced ... multi-center, randomized trial comparing the safety and effectiveness of ... ® , Abbott,s market-leading, permanent drug eluting stent. The ... Japan and enrolled 400 people with coronary ... The results will be featured at a late-breaking session ...
(Date:9/1/2015)... Quebec , Sept. 1, 2015  Valeant ... TSX: VRX) today announced that its affiliate has ... which Valeant was granted an exclusive license to ... is an IL-17 receptor monoclonal antibody in development ... arthritis. Under the agreement, Valeant will hold the ...
(Date:8/31/2015)... TWINSBURG, Ohio , Aug. 31, 2015 /PRNewswire/ ... and applications, has acquired MACTek Corporation, a leading ... part of Pepperl+Fuchs, strategy to further extend its ... the WirelessHART market.    "We are ... to our existing portfolio," said Jim Bolin ...
Breaking Medicine Technology:Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
(Date:9/1/2015)... ... September 01, 2015 , ... ... a next-generation customer communications archiving solution integrated with Alfresco‘s enterprise content management ... and helps organizations save millions of dollars in printing costs by digitizing ...
(Date:9/1/2015)... ... ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® , is ... treatment for volume loss in the hands. RADIESSE provides an immediate volumizing effect and ... smooth, natural-looking results that can last up to one year in most patients. Treating ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In America”, ... look at the topic of arthritis. There are over 100 different types of arthritis. ... types and statistics in an effort to shed light on this important topic. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for the ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs ... hours of new premium on-demand video Evidence Based Practice courses ... before 2014 must complete 50 CEUs before December 31, 2015, which must include ...
Breaking Medicine News(10 mins):Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2
... -- The growing number of people with Alzheimer,s disease in ... a responsibility that health experts warn can pose risks to ... to protect their health, says Rebecca Axline, a clinical social ... To keep stress in check, for instance, she emphasizes the ...
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- ... sugar control, often sending people with type 2 diabetes ... that happens. Now, a new study provides some ... decline dramatically in those who have the bypass surgery, ...
... brainy bookworms unprepared for the rough and tumble of post-graduation ... tend to fade away quickly when injected into cancer patients. ... can cause such cells to survive in patients, bloodstreams for ... of other, highly toxic treatments, a new study shows. ...
... Researchers in New York City say they are the first ... cells. A team at Albert Einstein College of Medicine ... gene transcription in living yeast cells, they say. Transcription occurs ... messenger RNA (mRNA) that then make the protein coded by ...
... , WEDNESDAY, April 27 (HealthDay News) -- An ... than earlier medications will be reviewed Thursday by a panel ... Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be ... levels of the virus, which can cause severe liver damage, ...
... (ASTRO) has developed a guideline for the use of ... to palliate thoracic symptoms caused by advanced lung cancer. ... Oncology , an official journal of ASTRO. Many patients ... treat symptoms related to cancer, such as cough, shortness ...
Cached Medicine News:Health News:Alzheimer's Caregivers Need Care, Too 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 2Health News:New technique extends cancer-fighting cells' potency in melanoma patients 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 4Health News:Researchers Describe Gene Activity in Living Cells 2Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:ASTRO publishes evidence-based guideline for thoracic radiotherapy 2
... years of experience in providing versatile ... Sciences, the Freedom EVO platform delivers ... expansion according to future needs., ,Together ... EVOware, each system is equipped to ...
... A flexible liquid ... simultaneously automate functionality of ... handlers all on the ... preconfigured in smart solutions ...
... The Centra B+ can be used as ... to the Centra W for AHG spins, or ... of 2 rotors, transparent cell washing rotor: easy ... 2 braking options, aerosol containment for vacutainers, glove ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
Medicine Products: